Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 541

1.

Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men.

Neslund-Dudas CM, McBride RB, Kandegedara A, Rybicki BA, Kryvenko ON, Chitale D, Gupta N, Williamson SR, Rogers CG, Cordon-Cardo C, Rundle AG, Levin AM, Dou QP, Mitra B.

J Trace Elem Med Biol. 2018 Jul;48:233-238. doi: 10.1016/j.jtemb.2018.04.006. Epub 2018 Apr 13.

PMID:
29773186
2.

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A.

Nature. 2018 Feb 22;554(7693):554. doi: 10.1038/nature25470. Epub 2018 Jan 17.

PMID:
29342137
3.

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, Pandolfi PP.

Nat Genet. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15.

PMID:
29335545
4.

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel.

Mohr L, Carceles-Cordon M, Woo J, Cordon-Cardo C, Domingo-Domenech J, Rodriguez-Bravo V.

J Vis Exp. 2017 Sep 8;(127). doi: 10.3791/56327.

PMID:
28930981
5.

Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation.

Pozo E, Castellano JM, Kanwar A, Deochand R, Castillo-Martin M, Pazos-López P, González-Lengua C, Osman K, Cham M, Cordon-Cardo C, Narula J, Fuster V, Sanz J.

J Card Fail. 2018 Feb;24(2):78-86. doi: 10.1016/j.cardfail.2017.08.445. Epub 2017 Aug 8.

PMID:
28801077
6.

Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernández-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zúñiga-García P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martín-Martín N, Sutherland JD, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A.

Nat Cell Biol. 2017 Jun 29;19(7):873. doi: 10.1038/ncb3558.

PMID:
28659639
7.

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A.

Nature. 2017 Jul 6;547(7661):109-113. doi: 10.1038/nature22964. Epub 2017 Jun 28. Erratum in: Nature. 2018 Jan 17;:.

8.

PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth.

Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, Saraf A, Florens L, Washburn MP, Collazo-Lorduy A, Castillo-Martin M, Cordon-Cardo C, Sebti SM, Pinton P, Pagano M.

Nature. 2017 Jun 22;546(7659):554-558. doi: 10.1038/nature22965. Epub 2017 Jun 14.

9.

Targeting sarcoma tumor-initiating cells through differentiation therapy.

Han D, Rodriguez-Bravo V, Charytonowicz E, Demicco E, Domingo-Domenech J, Maki RG, Cordon-Cardo C.

Stem Cell Res. 2017 May;21:117-123. doi: 10.1016/j.scr.2017.04.004. Epub 2017 Apr 13.

10.

miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy.

Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM.

Genes Dev. 2017 Mar 15;31(6):553-566. doi: 10.1101/gad.292318.116.

11.

The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein.

Chen M, Nowak DG, Narula N, Robinson B, Watrud K, Ambrico A, Herzka TM, Zeeman ME, Minderer M, Zheng W, Ebbesen SH, Plafker KS, Stahlhut C, Wang VM, Wills L, Nasar A, Castillo-Martin M, Cordon-Cardo C, Wilkinson JE, Powers S, Sordella R, Altorki NK, Mittal V, Stiles BM, Plafker SM, Trotman LC.

J Cell Biol. 2017 Mar 6;216(3):641-656. doi: 10.1083/jcb.201604025. Epub 2017 Feb 13.

12.

Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.

Donovan MJ, Cordon-Cardo C.

Mol Diagn Ther. 2017 Apr;21(2):115-123. doi: 10.1007/s40291-016-0249-5. Review.

PMID:
28000172
13.

Reappraising hyalinizing clear cell carcinoma: A population-based study with molecular confirmation.

Hernandez-Prera JC, Kwan R, Tripodi J, Chiosea S, Cordon-Cardo C, Najfeld V, Demicco EG.

Head Neck. 2017 Mar;39(3):503-511. doi: 10.1002/hed.24637. Epub 2016 Nov 29.

PMID:
27898192
14.

The role of GATA2 in lethal prostate cancer aggressiveness.

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J.

Nat Rev Urol. 2017 Jan;14(1):38-48. doi: 10.1038/nrurol.2016.225. Epub 2016 Nov 22. Review.

15.

Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.

Shukla-Dave A, Castillo-Martin M, Chen M, Lobo J, Gladoun N, Collazo-Lorduy A, Khan FM, Ponomarev V, Yi Z, Zhang W, Pandolfi PP, Hricak H, Cordon-Cardo C.

Am J Pathol. 2016 Dec;186(12):3131-3145. doi: 10.1016/j.ajpath.2016.08.021. Epub 2016 Oct 19.

16.

Protein Profiling of Bladder Urothelial Cell Carcinoma.

Hu J, Ye F, Cui M, Lee P, Wei C, Hao Y, Wang X, Wang Y, Lu Z, Galsky M, McBride R, Wang L, Wang D, Cordon-Cardo C, Wang C, Zhang DY.

PLoS One. 2016 Sep 14;11(9):e0161922. doi: 10.1371/journal.pone.0161922. eCollection 2016.

17.

The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.

Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernández-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zúñiga-García P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martín-Martín N, Sutherland JD, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A.

Nat Cell Biol. 2016 Jun;18(6):645-656. doi: 10.1038/ncb3357. Epub 2016 May 23. Erratum in: Nat Cell Biol. 2017 Jun 29;19(7):873.

18.

Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.

Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD.

Eur Urol. 2016 Nov;70(5):771-775. doi: 10.1016/j.eururo.2016.04.037. Epub 2016 May 10.

19.

Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma.

Grau JJ, Mesía R, de la Iglesia-Vicente M, Williams ES, Taberna M, Caballero M, Larque AB, de la Oliva J, Cordón-Cardo C, Domingo-Domenech J.

Oncology. 2016;90(5):267-72. doi: 10.1159/000445118. Epub 2016 Apr 15.

PMID:
27077749
20.

Immunopathologic Assessment of PTEN Expression.

Castillo-Martin M, Thin TH, Collazo Lorduy A, Cordon-Cardo C.

Methods Mol Biol. 2016;1388:23-37. doi: 10.1007/978-1-4939-3299-3_3.

PMID:
27033068
21.

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells.

Williams ES, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J.

J Vis Exp. 2015 Oct 20;(105):53182. doi: 10.3791/53182. Erratum in: J Vis Exp. 2015;(106):e5759. Rodriquez-Bravo, Veronica [corrected to Rodriguez-Bravo, Veronica].

22.

H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.

Castillo-Martin M, Collazo Lorduy A, Gladoun N, Hyun G, Cordon-Cardo C.

J Pediatr Urol. 2016 Apr;12(2):91.e1-7. doi: 10.1016/j.jpurol.2015.08.020. Epub 2015 Oct 22.

PMID:
26522772
23.

Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.

Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, Márquez J, Matés JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA.

Nat Med. 2015 Oct;21(10):1182-9. doi: 10.1038/nm.3955. Epub 2015 Sep 21.

24.

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target.

Shantha Kumara H, Kirchoff D, Caballero OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ, Cordon-Cardo C, Whelan RL.

Oncoscience. 2015 Jul 1;2(6):607-14. eCollection 2015.

25.

Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM.

Genes Dev. 2015 Aug 1;29(15):1631-48. doi: 10.1101/gad.262642.115. Epub 2015 Jul 30.

26.

PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.

Barber AG, Castillo-Martin M, Bonal DM, Jia AJ, Rybicki BA, Christiano AM, Cordon-Cardo C.

Cancer Med. 2015 Aug;4(8):1258-71. doi: 10.1002/cam4.463. Epub 2015 May 29.

27.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

28.

Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma.

Puzio-Kuter AM, Laddha SV, Castillo-Martin M, Sun Y, Cordon-Cardo C, Chan CS, Levine AJ.

Cell Death Differ. 2015 Nov;22(11):1785-91. doi: 10.1038/cdd.2015.27. Epub 2015 Mar 27.

29.

Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN.

Ugalde-Olano A, Egia A, Fernández-Ruiz S, Loizaga-Iriarte A, Zuñiga-García P, Garcia S, Royo F, Lacasa-Viscasillas I, Castro E, Cortazar AR, Zabala-Letona A, Martín-Martín N, Arruabarrena-Aristorena A, Torrano-Moya V, Valcárcel-Jiménez L, Sánchez-Mosquera P, Caro-Maldonado A, González-Tampan J, Cachi-Fuentes G, Bilbao E, Montero R, Fernández S, Arrieta E, Zorroza K, Castillo-Martín M, Serra V, Salazar E, Macías-Cámara N, Tabernero J, Baselga J, Cordón-Cardo C, Aransay AM, Villar AD, Iovanna JL, Falcón-Pérez JM, Unda M, Bilbao R, Carracedo A.

Methods. 2015 May;77-78:25-30. doi: 10.1016/j.ymeth.2015.02.005. Epub 2015 Feb 16. Review.

30.

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J.

Cancer Cell. 2015 Feb 9;27(2):223-39. doi: 10.1016/j.ccell.2014.11.013.

31.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP.

Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.

32.

A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells.

Guarnerio J, Riccardi L, Taulli R, Maeda T, Wang G, Hobbs RM, Song MS, Sportoletti P, Bernardi R, Bronson RT, Castillo-Martin M, Cordon-Cardo C, Lunardi A, Pandolfi PP.

Cancer Discov. 2015 Apr;5(4):396-409. doi: 10.1158/2159-8290.CD-14-1022. Epub 2015 Jan 22.

33.

TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation.

Epping MT, Lunardi A, Nachmani D, Castillo-Martin M, Thin TH, Cordon-Cardo C, Pandolfi PP.

Cell Death Differ. 2015 Aug;22(8):1353-62. doi: 10.1038/cdd.2014.226. Epub 2015 Jan 23.

34.

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM.

Nat Commun. 2015 Jan 22;6:6087. doi: 10.1038/ncomms7087.

35.

Limited miR-17-92 overexpression drives hematologic malignancies.

Danielson LS, Reavie L, Coussens M, Davalos V, Castillo-Martin M, Guijarro MV, Coffre M, Cordon-Cardo C, Aifantis I, Ibrahim S, Liu C, Koralov SB, Hernando E.

Leuk Res. 2015 Mar;39(3):335-41. doi: 10.1016/j.leukres.2014.12.002. Epub 2014 Dec 10.

36.

Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Di Sante G, Pestell TG, Casimiro MC, Bisetto S, Powell MJ, Lisanti MP, Cordon-Cardo C, Castillo-Martin M, Bonal DM, Debattisti V, Chen K, Wang L, He X, McBurney MW, Pestell RG.

Am J Pathol. 2015 Jan;185(1):266-79. doi: 10.1016/j.ajpath.2014.09.014.

37.

ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.

Gaya JM, López-Martínez JM, Karni-Schmidt O, Bonal DM, Algaba F, Palou J, Villavicencio H, Benson MC, Cordon-Cardo C, Castillo-Martin M.

J Urol. 2015 Apr;193(4):1144-50. doi: 10.1016/j.juro.2014.10.098. Epub 2014 Oct 28.

PMID:
25444981
38.

Biomarkers for bladder cancer management: present and future.

Ye F, Wang L, Castillo-Martin M, McBride R, Galsky MD, Zhu J, Boffetta P, Zhang DY, Cordon-Cardo C.

Am J Clin Exp Urol. 2014 Apr 5;2(1):1-14. eCollection 2014. Review.

39.

Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers.

Donovan MJ, Cordon-Cardo C.

Expert Rev Mol Diagn. 2014 Nov;14(8):1023-31. doi: 10.1586/14737159.2014.965151. Review.

PMID:
25327491
40.

The microRNA 424/503 cluster reduces CDC25A expression during cell cycle arrest imposed by transforming growth factor β in mammary epithelial cells.

Llobet-Navas D, Rodriguez-Barrueco R, de la Iglesia-Vicente J, Olivan M, Castro V, Saucedo-Cuevas L, Marshall N, Putcha P, Castillo-Martin M, Bardot E, Ezhkova E, Iavarone A, Cordon-Cardo C, Silva JM.

Mol Cell Biol. 2014 Dec 1;34(23):4216-31. doi: 10.1128/MCB.00611-14. Epub 2014 Sep 29.

41.

Bladder cancers arise from distinct urothelial sub-populations.

Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, Schneider K, Oyon D, Dunlop M, Wu XR, Cordon-Cardo C, Mendelsohn C.

Nat Cell Biol. 2014 Oct;16(10):982-91, 1-5. doi: 10.1038/ncb3038. Epub 2014 Sep 14.

PMID:
25218638
42.

A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.

Herranz D, Ambesi-Impiombato A, Palomero T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M, Llobet-Navás D, Cordon-Cardo C, Clappier E, Soulier J, Ferrando AA.

Nat Med. 2014 Oct;20(10):1130-7. doi: 10.1038/nm.3665. Epub 2014 Sep 7.

43.

Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer.

Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM, Cordon-Cardo C.

PLoS One. 2014 Jun 4;9(6):e98786. doi: 10.1371/journal.pone.0098786. eCollection 2014.

44.

FBXW7 mutations in melanoma and a new therapeutic paradigm.

Aydin IT, Melamed RD, Adams SJ, Castillo-Martin M, Demir A, Bryk D, Brunner G, Cordon-Cardo C, Osman I, Rabadan R, Celebi JT.

J Natl Cancer Inst. 2014 May 16;106(6):dju107. doi: 10.1093/jnci/dju107. Print 2014 Jun.

45.

MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9.

Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C.

Br J Cancer. 2014 Jun 10;110(12):2945-54. doi: 10.1038/bjc.2014.245. Epub 2014 May 13.

46.

Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG, Saenger Y.

J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.

PMID:
24698703
47.

Isolation of cancer stem cells from human prostate cancer samples.

Vidal SJ, Quinn SA, de la Iglesia-Vicente J, Bonal DM, Rodriguez-Bravo V, Firpo-Betancourt A, Cordon-Cardo C, Domingo-Domenech J.

J Vis Exp. 2014 Mar 14;(85). doi: 10.3791/51332.

48.

The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland.

Llobet-Navas D, Rodríguez-Barrueco R, Castro V, Ugalde AP, Sumazin P, Jacob-Sendler D, Demircan B, Castillo-Martín M, Putcha P, Marshall N, Villagrasa P, Chan J, Sanchez-Garcia F, Pe'er D, Rabadán R, Iavarone A, Cordón-Cardó C, Califano A, López-Otín C, Ezhkova E, Silva JM.

Genes Dev. 2014 Apr 1;28(7):765-82. doi: 10.1101/gad.237404.114. Epub 2014 Mar 17.

49.

Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.

Donovan MJ, Cordon-Cardo C.

Curr Opin Urol. 2014 May;24(3):303-10. doi: 10.1097/MOU.0000000000000051. Review.

PMID:
24625431
50.

RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.

Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC.

Cancer Discov. 2014 Mar;4(3):318-33. doi: 10.1158/2159-8290.CD-13-0346. Epub 2014 Jan 20.

Supplemental Content

Loading ...
Support Center